Biocytogen Launches “Nano 100 Project” to Develop Fully Human Nanobody Therapeutics for Over 100 Targets
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced the launch of the “Nano 100 Project”, which aims to develop fully human nanobody drugs for over 100 targets. The Project combines Biocytogen’s proprietary fully human nanobody mouse, RenNano®, with its high-throughput in vitro and in vivo antibody screening platforms to develop fully human nanobody drugs on a large-scale.
Compared to traditional antibodies, nanobodies have smaller molecular weights and improved tissue penetration ability, which make them effective at infiltrating tumors and crossing blood-brain barriers. Additionally, nanobodies generally have longer CDR3 regions which enables them to recognize hidden epitopes better. Due to their simpler structure, nanobodies are more stable and easier to produce and engineer, making them ideal building blocks for complex modalities such as cell therapy, bispecific antibody and engager, multi-specific antibody, antibody drug-conjugate (ADC), and radionuclide antibody-conjugate (RAC).
After several years of endeavor, Biocytogen successfully engineered the RenNano mouse from its fully human antibody mouse, RenMab™. RenNano mouse possesses full human heavy chain variable regions and can produce heavy-chain-only antibodies (HCAbs). The variable regions of HCAbs, i.e., nanobodies, do not require in vitro humanization to develop drugs. Our research has shown that RenNano mouse can generate robust immune responses after immunizations by different antigens. HCAbs generated from the RenNano mouse have highly diverse CDR3 sequences and can recognize many epitopes with nM-level high affinities. In vitro and in vivo experiments have shown that RenNano-derived antibodies have favorable biological functions.
Based on RenNano’s excellent ability to discover fully human nanobodies, Biocytogen has launched the “Nano 100 Project”. The Project aims to develop fully human therapeutic nanobodies against over 100 targets, including tumor associated antigens (TAAs), GPCRs, immune-checkpoints, cytokines, and factors related to neurological diseases. Biocytogen is actively seeking collaborations with global pharmaceutical and biotech companies to combine its large-scale nanobody development abilities with collaborators’ expertise in nanobody-related therapeutics, such as cell therapies, bispecific and multi-specific antibodies, ADCs and RACs, to develop novel drugs with first-in-class and/or best-in-class potentials.
“We believe that with the ability to rapidly develop fully human nanobodies against selected targets, the ‘Nano 100 Project’ will provide our global partners with more diverse and better nanobody building blocks to accelerate the development of novel drugs,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Meanwhile, it is also an important supplement to Biocytogen’s Project Integrum.”
About RenNano®
Biocytogen's proprietary fully human nanobody generating mouse, RenNano, is one of the most comprehensive fully human antibody platforms in the world. Nanobody sequences generated from RenNano mice have the highest possible diversity and do not require antibody humanization, which saves time and cost and reduces the risk of failure during later stages of drug development. Additionally, compared to natural HCAb-producing species like camelids, mice are easier to breed and immunize, making them suitable for developing HCAbs on a large scale.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab™/RenLite®/RenNano® mice platforms for fully human monoclonal antibody, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. This project has resulted in 28 drug co-development agreements and 16 RenMice™ licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230221005554/en/
Contact information
Biocytogen
Antibody platforms and antibody assets: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Green Street Expands Private Market Coverage with European Self-Storage Data and Analytics13.5.2025 11:00:00 EEST | Press release
Green Street, the foremost provider of commercial real estate intelligence and insights, has expanded its private market research coverage to the European self-storage sector. Utilising 5 years of forecasted insights and 10 years of historical data, Green Street’s new Self-Storage Outlook focuses on investment opportunities available in 30 European cities. “Living quarters are becoming more compact and storage space is being cut back in urban developments, necessitating off-premises storage solutions for residential occupiers. Additionally, approximately 40% of the business customer base consists of small-to-medium-sized entities, particularly online retailers in the region,” said Marie Dormeuil, Head of European Market Analytics. “The growth in real spending on storable goods is expected to increase at 2% per annum over the next five years, supporting healthy demand growth.” Green Street continues to invest in product innovation and expanding its breadth of research coverage by unveil
Oracle and Infobip Enhance Partnership to Deliver Global Conversational Experiences13.5.2025 11:00:00 EEST | Press release
Global cloud communications platform Infobip today announced that it has enhanced its partnership with Oracle to bring conversational experiences to businesses and brands globally. The new integration enables Infobip and Oracle customers and partners to access Infobip's omnichannel services through Oracle Integration. Customers increasingly expect omnichannel communications, but integrating and managing new channels can be time-consuming, requiring complex development, deployment, and organizational processes. Infobip’s new Omnichannel Messaging Adapter for Oracle Integration addresses this challenge byenabling all types of businesses to work with and manage omnichannel messaging channels involving Oracle and third-party solutions, including WhatsApp and RCS. The solution deploys quickly, reducing time to market. In addition, Infobip has provided a prebuilt use case – or Accelerator – for Oracle’s contact center solution, Oracle B2C Service. This Accelerator is a flexible solution that
Galeria Teams Up With Blue Yonder to Enhance the In-Store and Online Customer Shopping Experience13.5.2025 11:00:00 EEST | Press release
In today's rapidly evolving retail landscape, consumers increasingly seek personalized shopping experiences tailored to meet their specific demand requirements. For omni-channel retailers, success depends on seamlessly delivering high-quality products and excellent customer service powered by advanced technology that effectively supports a demand-driven, omni-channel strategy. That is why Galeria, Germany´s leading department store chain, has chosen to deploy Blue Yonder’s demand and replenishment capabilities to strengthen its supply chain and enhance operational efficiency. This strategic investment enables the retailer to deliver a highly responsive and seamless shopping experience across both in-store and online channels, reinforcing Galeria's commitment to quality and convenience. Galeria previously relied mainly on manual processes that limited the company’s ability to forecast demand and accurately allocate inventory across its stores. Through strong collaboration between Galeri
SecurityBridge Teams up With Microsoft to Enhance SAP Security With Microsoft Sentinel13.5.2025 10:17:00 EEST | Press release
SecurityBridge, the Cybersecurity Command Center for SAP, is pleased to announce its collaboration with Microsoft to integrate SAP data into Microsoft Sentinel. The integration enables SecurityBridge to seamlessly share SAP security events with Microsoft Sentinel’s cloud-native security information and event management (SIEM)—enhancing the visibility to detect and respond to threats across SAP landscapes when it matters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513088279/en/ SecurityBridge x Microsoft Sentinel in action. "This close collaboration represents a significant advancement in SAP security. Combining our SAP-native cybersecurity platform with Microsoft Sentinel’s capabilities makes complex SAP security events accessible and actionable for all security teams, ultimately supplying customers with the knowledge to better secure SAP systems from threats," said Ivan Mans, CTO & Co-Founder, SecurityBridge. SAP sys
Saildrone Closes $60M Financing to Bring Maritime Autonomy to Europe13.5.2025 10:05:00 EEST | Press release
Saildrone, the global leader in maritime autonomy, today announced the closing of a $60 million investment round led by EIFO, the Export and Investment Fund of Denmark. The investment will be used to bring Saildrone technology to Europe to address the urgent need for maritime security for critical infrastructure and wider defense applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513296505/en/ Four Saildrone Voyager uncrewed surface vehicles (USVs) will be deployed in Danish waters during the summer of 2025 in partnership with the Danish Armed Forces. The operational testing will begin in June and is part of a broader effort to integrate uncrewed systems into Denmark’s defense architecture. The Baltic, North Sea, and European Arctic waters are currently facing unprecedented threats, and the need for persistent maritime domain awareness has never been greater. Saildrone’s extreme endurance unmanned surface vehicl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom